Innovation

Harnessing innovative technology in drug discovery

Merck scientists explain how new technologies can accelerate the drug discovery process as we use the power of leading-edge science to save and improve lives

November 16, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

scientist in the lab

Our scientists are leveraging state-of-the-art capabilities to discover novel molecules that may lead to the medicines of tomorrow. 

Merck Research Laboratories (MRL) scientists evaluate hundreds to thousands to up to billions of compounds to find a starting point for a new drug candidate. It all starts with identifying a target — usually a protein — that’s intrinsically associated with a particular disease and can be pharmacologically modulated. That’s where innovative tools like structure-based design, high-throughput screening and high-throughput experimentation, coupled with robotics, artificial intelligence and machine learning can make a huge difference in progressing the work. And once a lead molecule is identified, cryogenic electron microscopy (cryo-EM) as an emerging structural method can be used to understand and improve how a molecule interacts with the protein target.

Utilizing the latest technologies and diligent work by teams of highly skilled and experienced scientists can potentially accelerate the discovery of new medicines for patients in need.

“We have an incredibly creative, smart and hardworking workforce. It’s an absolute pleasure to be part of that and to have access to the resources necessary for making scientific breakthroughs.”

— Adam Weinglass

Executive director in quantitative biosciences
Innovation

Breaking new ground in the UK

We’re accelerating our global efforts and capabilities with our new London Discovery Research Centre and U.K. headquarters

November 10, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

3 people with hard hats breaking ground

Using the power of leading-edge science to help save and improve lives means tapping into scientific talent around the world. That’s why we’re proud to break ground on our new London Discovery Research Centre and U.K. headquarters.

The high-profile site — located opposite King’s Cross Station in the heart of London’s Knowledge Quarter, an impressive cluster of academic, scientific and technological institutions — will be an impactful addition to our growing network of research facilities.

“Our talented discovery scientists in London are an integral part of our global research network.”

  • Dean Li
    President of Merck Research Laboratories

“Patients around the world are waiting for innovations that will help confront the tremendous burden of disease they face, and the kind of world-class scientific exploration this facility will enable is how we accelerate those innovations,” Li added.

Slated to open in 2027, the 270,000-square-foot, 10-story facility will bring together all our U.K. colleagues to help drive medical advances against some of today’s greatest health challenges.  

“With the benefit of London’s thriving life sciences ecosystem and Knowledge Quarter right on our doorstep, I’m excited about the collaboration opportunities, building toward an exciting new chapter, and what this represents for employees and our partnership with the local community and beyond,” said Ben Lucas, managing director, U.K. and Ireland.

Health awareness

The new generation making an impact on HIV

Meet these young advocates helping to lead the response to HIV around the world

November 10, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

HIV young leaders collage

HIV remains a global pandemic. In 2022 alone, an estimated 1.3 million people worldwide were newly diagnosed with HIV.

Merck has been committed to advancing science for the treatment and prevention of HIV for more than 35 years, but we know it takes all of us to make a difference for the HIV community.

And that’s just what these International AIDS Society (IAS) Young Leaders are doing. In 2022, our company was proud to be one of the groups to support 11 Young Leaders to co-create the Youth Hub — a youth-led networking platform that empowers young change-makers living with and affected by HIV to lead in the HIV response. They’re an inspiring group of advocates with different backgrounds and experiences in the response to HIV, each striving to empower and educate others from their respective corners of the globe.

Let’s meet some of these young change-makers.

Norman Chong | Malaysia

Norman Chong is using their gift of storytelling to encourage young people across the world to ask “Why?” Chong has been working to develop a solution-oriented platform to help address gaps in the HIV response for young people in Malaysia.

With their platform, called “We Ask the Y (WAY)”, Chong aims to provide tools for young people living with and affected by HIV to learn and network in support of social health, as well as economic and political justice. Chong also trains young researchers to translate and communicate findings into evidence-informed policies and practices to address barriers to health care for young people.

“If I have anything at all, it’s anchored on moving the dial with the question, “Why?”, and advocating for health care to be accessible to all, for policies designed to protect and empower, and never to divide and conquer.”

  • Norman Chong

Linda Joseph Robert | Uganda

Dismantling HIV stigma to support young people is the motivation for everything Linda Joseph Robert does. As a youth advocate, he helps to promote increased access to quality adolescent sexual and reproductive health services for young people through peer support interventions, community engagements and strategic partnerships. His passion for youth advocacy, activism and HIV-related programming came to life when he led a campaign to help reduce HIV stigma and discrimination during the COVID-19 pandemic.

As a young person living with HIV, Robert is driven to help increase access to HIV prevention, treatment and care services. Robert has held leadership positions including the role of youth advocate at AIDS Healthcare Foundation-Uganda Cares, and serves as a U=U Africa Forum Ambassador in Uganda.

“I’m motivated by the progress that has been made in the HIV field and excited to be part of the next generation of HIV professionals who will continue the journey toward ending the AIDS pandemic, where no one is left behind.”

  • Linda Joseph Robert

Elizabeth Onyango | Kenya

UKIMWI UNAUA is a term Elizabeth Onyango and others in Kenya know too well. Translated to “HIV kills,” this phrase influenced Onyango’s perception of HIV at a young age — as the messaging around HIV in her country was mostly about death and fear. Growing up, she lost close family and friends to HIV and saw how cultural beliefs and practices exposed young women and girls to HIV. It wasn’t until she went to high school that Onyango learned about ways to protect against HIV, which helped reduce the fear she grew up with — and sparked an interest in HIV prevention.

After high school, she volunteered at a female sex worker-led organization that champions human and health rights of sex workers. Today, Onyango continues to encourage young women to take action to ensure they have a say in decisions about their health.

“My goal is to champion meaningful engagement of women and girls in HIV prevention and advocate for structural changes to improve the quality of life of women living with HIV.”

  • Elizabeth Onyango

Isaac Ogunkola | Nigeria

A background in public health has given Isaac Ogunkola deep insight into the world of infectious diseases, especially HIV. His passion for HIV advocacy became clear after volunteering to encourage harm reduction for people who use drugs and promote sexual and reproductive health and rights programming for homeless children, refugees and young people.

Having witnessed young people in his community die as a result of drug overdose and HIV, Ogunkola is committed to unifying public health, harm reduction and human rights. Through his peer education project, he engages young refugees in West Africa to lead HIV prevention programs in their communities.

“I don’t want to see death in any age group or population caused by HIV or drug overdose again.”

  • Isaac Ogunkola

Ashley Rose Murphy | Canada

Ashley Murphy was 7 years old when her adoptive parents told her she was living with HIV. By age 10, Murphy began to speak publicly about living with HIV, talking to young people around the world about the stigma around HIV and how to protect and advocate for themselves. She’s been a key voice for youth activists engaged in the HIV response in Canada ever since presenting at the U.N. General Assembly and the Global Fund, and even hosting a TED Talk.

Today, Murphy is an ambassador for several foundations committed to ending the AIDS epidemic through research, government-funded programs, global advocacy, prevention, testing and treatment options. Murphy remains an inspiration for young Canadians living with or affected by HIV.

Ashley Rose Murphy

“I want everyone to know that an HIV diagnosis does not have to be the end of the world. We can continue to live healthy and fulfilling lives, but it starts with educating yourself about your diagnosis and, most importantly, being your own advocate.”

  • Ashley Rose Murphy

Paul Mavesere Ndhlovu | Zimbabwe

Paul Ndhlovu has been using his voice to help young people living with and vulnerable to HIV in his native Zimbabwe for years. He’s produced a peer-led radio show as the creative radio champion for Zvandiri, an organization that “connects children and young people living with HIV with peer counselors to help assure health, happiness and hope.”

In his role, Ndhlovu — together with other adolescents and young people — has created a youth-friendly environment for people living with HIV to freely discuss challenges and issues in their own lives. The show explains to young people the importance of HIV prevention behaviors, the need for increased HIV testing, their sexual and reproductive rights, and available resources to help with mental health and well-being needs.

Paul Mavesere Ndhlovu

“The Zvandiri Radio Show is such an important platform. We’re providing an open forum for people living with HIV to freely come as themselves and talk about any challenges they may face.”

  • Paul Mavesere Ndhlovu

Stefano Regner | Philippines

Stefano Regner’s schedule is always busy, and as a physiotherapist and sexual health advocate, his work revolves around helping others.

As a trained HIV screener, counselor, and speaker, Regner is constantly on the move — traveling across the Philippines to help link people living with HIV to immediate care and empowering people when it comes to understanding safer sex. He’s also been a research assistant for one of the Philippines’ largest grassroots HIV test-and-treat centers.

And today, as both a medical student and a social media influencer, Regner provides educational resources for people living with HIV, using health campaigns and videos.

Stefano Regner

“Social media provides a new platform and method to translate and communicate important topics about health and increasing health literacy. I enjoy sharing key information with my followers, especially as it relates to sexual and reproductive health among at-risk populations in the Philippines.”

  • Stefano Regner

Kalisito Biaukula | Fiji

Kalisito Biaukula’s motivation to give a voice to the voiceless and speak up for those in need is evidenced by their work across their island nation of Fiji and surrounding regions. 

As an intersectional, queer, feminist activist and human rights defender, Biaukula has worked with various civil society organizations addressing intersecting human rights issues for people with diverse sexual orientations, gender identities and expressions, and sex characteristics, in Asia and the Pacific.

Biaukula is a major advocate for people living with and impacted by HIV, fighting to ensure they receive the proper care and government assistance, and calling for comprehensive sexuality education at all levels.

Kalisito Biaukula

“It’s important for young people, especially those living in the Asia-Pacific region, to take a leading role in decisions that affect our bodies. We must all use our voices to stand up for human rights and ensure all populations are receiving equal opportunities to access care.”

  • Kalisito Biaukula

Sara Thapa Magar | Nepal

From a young age, Sara Magar developed an interest in social issues related to women and children living with HIV. This passion eventually led her to advocate for the needs and rights of affected populations living in the Asia-Pacific region.

Magar has been a board member of the International Community of Women Living with HIV Asia & Pacific (ICWAP) and has also spoken publicly about the need to support women-led organizations. In her current role as president of the National Federation of Women Living with HIV and AIDS (NFWLHA) in Nepal, Magar works to tackle gender inequalities and end gender-based violence.

Sara Thapa Magar

“As youth leaders, we need to continue bringing these issues to the forefront and work to partner with the government and advocacy groups to address the challenges of women and children living with HIV.”

  • Sara Thapa Magar

The future is in good hands with these young leaders, advocates and activists, and we’re excited to continue to watch the impact they make on their local and global communities. To learn more about this youth-led collaboration, visit the IAS Youth Hub.

Health awareness

How you can help slow the threat of antimicrobial resistance

The growing burden of AMR is threatening the return to a world without effective antibiotics

October 30, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Mother and daughter washing hands

Before antibiotics were discovered in the 20th century, contracting an infection could be fatal. Their discovery was a turning point in human history, revolutionizing medicine and saving countless lives. However, the growing burden of antimicrobial resistance (AMR) is threatening the return to a world without effective antibiotics.

We all have a responsibility to address this threat, and it will take dedicated efforts from all sectors across health care, including patients, to make a difference.

Here are four groups that can play a role in helping slow the threat of AMR:

01.

Patients

Be vigilant in infection prevention efforts and always use antibiotics correctly

We each play an important role in slowing the threat of AMR— starting with preventing infections that require antibiotics in the first place. Washing hands, preparing food hygienically and keeping up to date with vaccinations are all measures to help avoid infections.

Another important action patients can take is using antibiotics only when they’re needed. Always follow health care providers’ (HCPs) directions and never share or take leftover antibiotics, which may not be needed and may cause resistance. If your HCP believes antibiotics are not the correct treatment to help your condition, ask about other options. Taking antibiotics when they’re not needed may advance AMR. Bottom line: It is important to follow the guidance that your medical team gives you for treatment.

Antimicrobial resistance pill

02.

Health care professionals

Be a source of antibiotic guidance

HCPs and medical systems need to preserve the effectiveness of antibiotics. It’s up to the health care providers to help ensure that the right treatment is given based on an accurate diagnosis. Hospitals should have a plan in place, with principles customized to their local needs, to guide the appropriate use of these medicines.

Nurse consulting patient

03.

Policymakers

Encourage antimicrobial innovation

We need new antibiotic options to stay ahead of the evolving bacteria. Governments can help. Incentive packages can provide a sustainable return on investment for the development of new antimicrobials. Encouraging innovation would allow companies to invest in the research and development needed. As a result, this would help provide health care professionals around the world with the tools they need to help patients fighting infections.

Signature

04.

Industry leaders

Invest in new developments

Finally, the participation of leading biopharmaceutical companies is crucial to addressing the growing threat of AMR.

For more than 100 years, Merck has played a significant role in the discovery and development of novel medicines and vaccines to combat infectious diseases. And, in an effort to affect widespread change, we’ve supported efforts around the world that aim to address AMR through surveillance initiatives, collaborating with hospitals to fund education and implement stewardship programs, and advocating for substantial policy changes.

Researcher in the lab

There is no single solution to the complex problem of AMR; it’s up to all of us to take collective action. We hope you’ll join our efforts and play your individual part to help ensure that patients have access to the antibiotics they need, now and in the future.

Health awareness

Staying positive with pulmonary arterial hypertension

From struggling to breathe to advocating for others, one woman with PAH shares her story

October 24, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

A decade ago, Nola Martin was having trouble breathing, and she was gaining weight. She assumed it was simple: She started to focus on improving her diet and getting more exercise, but she wasn’t seeing results.

“Little did I know the situation was a lot more serious than that,” she said.

Martin was diagnosed with pulmonary arterial hypertension (PAH) and scleroderma. PAH is a disease of high blood pressure in the lungs. Her PAH was associated with scleroderma, a connective tissue disease that can affect the skin, blood vessels and organs and can cause PAH.

“I had two illnesses, and I had no idea what they were from. How did I get them? I was hearing all these terms I’d never heard of before.”

  • Nola Martin

Finding the right care

Martin said that the confusion and complexity of having two chronic diseases made the beginning of her journey the most challenging. Through her experience with PAH, she said she learned that “you must find a facility that is familiar with your disease.” She recommends the Pulmonary Hypertension Association as a great place to start learning about PAH.

While she knows her PAH is progressive, she chooses to stay positive.

“What I learned about advocating for myself with PAH is that no one is going to fight as hard for me as I will,” said Martin. “I know my body. I know when something is different, but I also know that my doctors are not mind readers. If I don’t share with them what is going on, including the smallest details, they can’t give me the proper treatment I need.”

portrait of women in orange shirt

Staying hopeful through connection

It’s important to Martin to connect with other PAH patients and educate people about the disease.

Since her diagnosis, she’s educated numerous people about PAH and scleroderma. She believes in the importance of raising awareness and telling her story. It’s sometimes hard for her to explain to people that even if she doesn’t appear sick, she may still be dealing with difficult symptoms.

“PAH has affected so much of my daily life — simple things like vacuuming, doing the laundry, taking a shower and going to the grocery store,” Martin said. “I encourage others to be understanding and avoid making assumptions about a person with PAH based on their outward appearance.”

She urges people to be supportive and listen when someone shares their story.

Innovation

Merck’s legacy of antimicrobial innovation and action

Delivering on our commitment to fight infectious diseases for more than a century

October 12, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

scientist working with liquid

For more than 100 years, Merck has contributed to the discovery and development of novel medicines and vaccines to fight infectious diseases. With the growing burden of antimicrobial resistance (AMR), we’ve focused on stopping the increasing threat of AMR

1930s

Merck Research Laboratories played a central role in the development of sulfas, the first synthetic antimicrobial.

vials with background of industrial complex

1940s

In collaboration with Rutgers University, we developed streptomycin, the first antibiotic effective against tuberculosis. We also helped to develop one of the first methods for mass production of penicillin.

scientist taking out trey of vial

1950s & 1960s

We developed multiple novel methods to prevent infectious diseases, including pediatric vaccines.

scientist working with equipment

1970s & 1980s

We received U.S. Food and Drug Administration (FDA) approval for two vaccines, as well as three antibiotics that treat a variety of bacterial infections.

doctor holding patients right arm

1990s & 2000s

Merck received U.S. FDA approval for two antifungals, as well as licenses for two vaccines.​

2002

With resistance to antibiotics developing faster through people, animals and the environment, we launched one of the world’s largest and longest-running antimicrobial resistance surveillance studies. Called the Study for Monitoring Antimicrobial Resistance Trends (SMART), the program enables researchers to monitor and identify trends in the development of AMR.

2010s

We launched an Antimicrobial Stewardship (AMS) Investigator Initiated Studies program, supporting investigator-based, peer-reviewed research supporting the implementation of AMS principles across the globe, with over 20% of studies occurring in low-and middle-income countries.

large building

2016

We created the Merck Exploratory Science Center in Cambridge, Massachusetts, focusing on the earliest stages of research into the underlying biology of human disease.

2016-2017

We supported the first United Nations high-level meeting on AMR and subsequent political declaration in 2016, which set policy action on AMR in motion.

As a next step, we joined the newly founded AMR Industry Alliance – a network of over 100 pharmaceutical industry partners working to provide sustainable solutions to help curb antimicrobial resistance.

AMR action fund logo

2020

Merck, along with a group of more than 20 leading biopharmaceutical companies, launched the AMR Action Fund to bring 2-4 new antibiotics to patients by the end of the decade.

2020s

Our staff have championed government actions to create supportive markets for antimicrobial innovation, including the PASTEUR Act in the U.S., inclusion of transferable exclusivity extensions in the EU pharmaceutical strategy, and other incentives around the world.

By collaborating with policymakers, Merck aims to improve appropriate antibiotic use globally.

cow drinking milk from bottle

Going forward

In recognition of our leadership in both human and animal health, Merck represents industry in the One Health Global Leaders Group on Antimicrobial Resistance, which advocates for a One Health approach to help ensure antibiotics remain an important tool in improving and maintaining human and animal health.

Our people

Here for Good: A lifelong mission against HIV

A colleague transformed personal grief and tragedy into a lifelong mission to help persons living with HIV

October 12, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Richard Liu’s work in HIV began in 1988, and it’s continued to this day.

“At the time, many members of the community were not only scared and frightened about HIV, but many of them were suffering from either the disease itself or the discrimination and bias directed toward them,” Liu said. “For me, education and outreach was a way to feel empowered and to empower members of my community.”

He also experienced firsthand how devastating HIV could be, falling in love with a man he’d eventually lose to AIDS.

“I found my strength when I looked back and thought about all the situations that Scott and I faced, I learned I was stronger than I ever believed I was,” Liu said. “And I kind of knew after that I needed to do something more. My purpose at that time was loving and caring for him until the end, and I needed to find another purpose. And that purpose became fighting HIV.”

Liu followed that purpose into a role as one of Philadelphia’s youngest HIV program directors, focusing on promoting prevention, testing and care. His passion eventually brought him to Merck, where he is a member of our global marketing division assigned to the HIV franchise, leading the development of promotional content for health care providers.

“I'm doing exactly what I've always wanted to do: be useful, be valuable and use what I can to fight HIV. And I've been given this incredible role at this company to do that.”

— Richard Liu

As a part of the Merck team, Liu, now happily married, has always felt he could bring his authentic self to work — and that feeling started during his interview with a recruiter. There were some moments in his personal history during his earlier work as an AIDS activist that he knew he’d have to explain.

“I wanted to disclose my arrest record because I thought it might come up in a background check,” Liu explained. “I was charged with obstruction of highway because I was participating in AIDS protests, so I wanted to be clear why I was arrested and given those charges.”

The instinct to be candid was a good one, he learned.  “When I was offered the job, I really felt like, wow, this company is willing to recognize my authentic self, including my activism.”

Liu’s estimation of Merck and our values — and the part he can play in the work we do for patients — hasn’t changed.

“I feel like my fight against HIV is perfectly aligned with our company’s commitment toward innovation and to persons living with HIV,” he said.

Innovation

How we’re collaborating to address antimicrobial resistance – and why we can’t do it alone

Shared commitments like the AMR Action Fund are vital to make progress against this public health threat

September 8, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Antibiotics have transformed health care and saved countless lives. But rising levels of antimicrobial resistance (AMR) can make current antibiotics less effective. There’s no simple solution to the complex problem of AMR, but we’re committed to investing our expertise and resources alongside our partners to get antibiotics to those who need them most. Lives are at risk, and the time to act is now.

Through this groundbreaking partnership of over 20 leading pharmaceutical companies, philanthropies and organizations, we aim to bridge the gap between the innovative early antibiotic pipeline and patients. True to our legacy of preventing and treating infectious diseases, we’re proud of our commitment to invest $100 million over 10 years in the AMR Action Fund. The fund’s collective goal is to bring two to four novel antibiotics to patients and physicians by 2030.

As of early 2023, the AMR Action Fund has invested in five small biotech companies advancing research for new medicines to fight some of the most dangerous bacteria as determined by the U.S. Centers for Disease Control and Prevention and the World Health Organization.

Here are five reasons collaborative efforts are key to addressing AMR:

01.


New antibiotics are urgently needed; however, there are relatively few in development.

The future of antibiotic innovation is at serious risk. Major scientific, regulatory and economic challenges discourage innovation in antibiotics, resulting in a decline in the number of companies conducting antimicrobial R&D. Recognizing there’s no one-size-fits-all solution to the problem, our company and others have suggested a series of policy reforms across several regions of the world. However, time is running out. We need collaboration from policymakers to help antibiotic innovation flourish for decades to come.

02.

Once new antibiotics are approved, they need to be used responsibly.

At Merck, we’re making significant investments to support antimicrobial stewardship (AMS), a broad term for the implementation of evidence-based policies to slow resistance to current antimicrobials. Our investments and partnerships help hospitals around the world develop and implement patient-centered AMS programs that are customized locally based on factors like epidemiology, clinical setting and resource availability to support the responsible prescribing and use of antimicrobials. We also provide significant grant funding to support a wide range of AMS initiatives and collaborations.

Some of our global contributions to AMS include:

  • Supporting the development of several AMS Centers of Excellence throughout the world.
  • Helping public health leaders effectively monitor and address emerging AMR infections, promote AMS and customize accepted AMS strategies to meet local needs.
  • Providing significant grant-funding for numerous investigator-initiated AMS research projects.

03.

Tracking resistance trends and using data to help doctors prescribe the right medicines remains critical.

Our company has been tracking global resistance trends for over 20 years. This data helps doctors prescribe the right medicines. One of the largest and longest-running AMR surveillance programs, our Study for Monitoring Antimicrobial Resistance Trends (SMART) program has collected nearly 500,000 Gram-Negative bacterial isolates from around 220 sites in more than 60 countries since 2002.

We’re also a partner of the AMR Register, a first-ever online platform that allows pharmaceutical companies to securely share data on infection-causing pathogens with researchers, national governments and multilateral organizations working to fight AMR.

04.

AMR extends beyond human health.

The challenge of AMR is multifaceted, and a One Health approach to creating policies is critical to attain optimal health for people, animals and the environment.

When it comes to animal health, vaccines can help minimize the need for antibiotics. Merck Animal Health is one of the largest manufacturers of animal health vaccines, supplying over 102 billion doses each year.

Protecting the environment through responsible manufacturing is another key component of the One Health approach. We work with our partners in the AMR Industry Alliance to inform science-based manufacturing standards to help ensure scrutiny of industry manufacturing supply chains.

05.

The time to act against AMR is now.

With collaboration across the scientific community and policymakers, AMR is preventable.

We all have a role to play as we prepare for the next health crisis. We must act now to put measures in place to ensure we have the antibiotics we need.

“AMR is not a future problem — it’s here now, threatening human, animal and environmental health as we know it. We must take swift, collaborative action to help reduce the risk of AMR before it’s too late,” said Jennifer Zachary, executive vice president and general counsel at Merck and member of the Global Leaders Group on AMR.

To learn more about the investments that the AMR Action Fund is making to help ensure patients and physicians have access to effective antimicrobials –- now and in the future –- please visit their website.

Innovation

Podcast: Why neuroscience is the ‘final frontier’

Listen as specialists from Merck discuss what they’re most excited about in researching potential treatments for neurologic disorders

July 11, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Four people in a modern office setting, with two seated on blue chairs and two standing behind them

Our scientists are revolutionizing how we discover and develop treatments to address unmet medical needs in a number of areas, including neuroscience.

“It’s sort of like the final frontier,” said Joe Herring, scientific AVP, clinical research, in our new podcast. “You’re going off into space to try to figure out how to do very difficult things.”

For more, listen in as Herring sits down with Merck clinical research team senior principal scientists Yuki Mukai and Ari Merola as well as business development director Paige Lacatena to explore today’s breakthroughs and challenges in the field of neuroscience.

Listen to the podcast

Read the full transcript

Explore careers in R&D at Merck

Man and women scientists in a lab

Careers

Are you interested in a career in R&D?

Our people

Podcast: Meet the dealmakers 

Merck’s business development and licensing team explain how they identify new opportunities to strengthen our robust R&D pipeline  

June 1, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

PodcastGroupattable

It takes a special kind of talent to find and secure the right deals to keep us at the forefront of innovation. Leaders from our business development and licensing team sat down to discuss how their work is a key component to building and maintaining a strong pipeline.  

Here’s what you need to know:  

01.

Harnessing our legacy

Our reputation for using leading-edge science can make business development connections easier, explains Lizabeth Leveille, vice president, business development.


02.

The speed and determination to get it done

Elizabeth Naldi-Jacob, vice president, business development, knows that having a direct line of reporting to the top is what sets Merck apart as a potential partner. 


03.

Balancing the internal and the external  

We have a one pipeline mindset, and each asset receives the same focus and rigor whether it comes from inside our company or out, says Christopher Mortko, vice president, business development. 


04.

Working hand-in-hand with our scientists  

Grace Han McMahon, associate vice president, business development, explains why engaging our internal science leaders is crucial to making the right deals. 


05.

What we’re interested in (and why it’s everything) 

Our panelists discuss why we focus on five key areas — and when we’re willing to look beyond them.


Great partnerships begin with great conversation. Learn more about how discovery & development and licensing shape the future of Merck.  

For more, check out the full podcast: 

four people behind the mic on the right stating meet the dealmakers on the left

Read the transcript